Website
News25/Ratings12
News · 26 weeks810%
2025-10-262026-04-19
Mix4890d
- Insider24(50%)
- Other10(21%)
- SEC Filings9(19%)
- Earnings4(8%)
- Analyst1(2%)
Latest news
25 items- INSIDERSEC Form 4 filed by Venker Eric4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERSEC Form 4 filed by Pulik Richard4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERSEC Form 4 filed by Humes Jennifer4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERSEC Form 4 filed by Oren Ilan4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERSEC Form 4 filed by Epperly Melissa B,4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERSEC Form 4 filed by Momtazee James C4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERSEC Form 4 filed by Gline Matthew4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- SECSEC Form 144 filed by Roivant Sciences Ltd.144 - Roivant Sciences Ltd. (0001635088) (Subject)
- INSIDERSEC Form 4 filed by Humes Jennifer4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERSEC Form 4 filed by Torti Frank4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- SECRoivant Sciences Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Roivant Sciences Ltd. (0001635088) (Filer)
- PRPriovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies exist for LPP, highlighting a critical unmet therapeutic needLPP marks the fourth indication in brepocitinib's expanding late-stage development programMultiple lines of evidence, including strong mechanistic rationale and clinically meaningful results in an investigator-initiated placebo-controlled study of brepocitinib in LPP, support rapid development of brepocitinib in this indicationA seamless Phase 2b/3 potentially registrational trial of brepocitinib in LPP enrolled its
- PRRoivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies exist for LPP, highlighting a critical unmet therapeutic needLPP marks the fourth indication in brepocitinib's expanding late-stage development programMultiple lines of evidence, including strong mechanistic rationale and clinically meaningful results in an investigator-initiated placebo-controlled study of brepocitinib in LPP, support rapid development of brepocitinib in this indicationA seamless Phase 2b/3 potentially registrational trial of brepocitinib in LPP enrolled its
- INSIDERSEC Form 4 filed by Gline Matthew4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERSEC Form 4 filed by Sukhatme Mayukh4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERSEC Form 4 filed by Fitzgerald Meghan4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- PRNew England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in DermatomyositisThe results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing potential of brepocitinib 30 mg once-daily in dermatomyositisBrepocitinib 30 mg was superior to placebo on the primary and all nine key secondary endpoints, with statistically significant and clinically meaningful improvements observed across measures of global disease activity, muscle strength, skin disease, physical function, and corticosteroid reductionAdditional analyses from VALOR, presented at the 2026 American Academy of Dermatology (AAD) Meeting, demonstrated meaningful improvements in itch and skin-related quality of life with brepocitinib 30 mgThe U.S. Fo
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.SCHEDULE 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)
- SECSEC Form 144 filed by Roivant Sciences Ltd.144 - Roivant Sciences Ltd. (0001635088) (Subject)
- INSIDERSEC Form 4 filed by Pulik Richard4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERSEC Form 4 filed by Humes Jennifer4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- SECAmendment: Roivant Sciences Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K/A - Roivant Sciences Ltd. (0001635088) (Filer)
- ANALYSTBernstein initiated coverage on Roivant Sciences with a new price targetBernstein initiated coverage of Roivant Sciences with a rating of Outperform and set a new price target of $35.00
- INSIDERSEC Form 4 filed by Venker Eric4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERSEC Form 4 filed by Epperly Melissa B,4 - Roivant Sciences Ltd. (0001635088) (Issuer)